Lastly, individuals with metastatic melanoma with a shorter tumor infiltrating lymphocyte doubling time had a higher response frequency to treatment with autologous tumor-infiltrating lymphocytes and interleukin 2 (Aebersold et al., 1991; Rosenberg et al., 1994). This evidence concerns the gene IL2 and neoplasm.